Thomas Meier Appointed as New CEO of Medios AG to Drive European Specialty Pharma Growth

The Supervisory Board of Medios AG has appointed Thomas Meier as a member of the Executive Board with effect from February 1, 2026, and designated him the new Chief Executive Officer of the Company. This leadership transition marks a significant strategic move for Medios AG, Germany's first listed specialty pharmaceutical company, as it positions itself for continued expansion in the European Specialty Pharma sector.

Thomas Meier brings substantial international pharmaceutical industry experience to his new role, having served as CEO of Swiss CDMO company Bachem Holding AG since 2020. His previous roles include Chief Operations Officer on the Executive Board of Bachem and Head of Manufacturing at Peninsula Laboratories in San Carlos, California, from 2001 to 2004. This diverse background across different pharmaceutical segments and international markets positions him well to lead Medios AG's next development phase.

Dr. Yann Samson, Chairman of the Supervisory Board of Medios AG, emphasized the strategic importance of this appointment, stating that Meier's international experience and track record of capital-efficient, profitable growth will contribute significantly to achieving the company's ambitious goals. The leadership change comes as Medios AG continues to strengthen its position as a leading provider of Specialty Pharma in Europe, with operations spanning Germany, the Netherlands, Belgium, and Spain.

The appointment signals Medios AG's commitment to maintaining its growth trajectory in the competitive European pharmaceutical market. Thomas Meier expressed his enthusiasm for leading Medios into its next development phase, emphasizing his intention to continue developing the company's successful strategy and sustainably expanding Medios' position in the European Specialty Pharma market. This leadership transition occurs as the company prepares for important financial reporting milestones, including the Quarterly Statement as of September 30, 2025, scheduled for November 11.

For investors and industry observers, this CEO appointment represents Medios AG's strategic focus on maintaining its pioneering role in individualized medicine. The company's mission to make innovative therapies available through partnerships with pharmacies, specialist practices, and pharmaceutical companies aligns with growing global demand for personalized healthcare solutions. More information about the company's approach to individualized medicine can be found at https://app.medios.group/en/individualizedmedicine.

The leadership transition follows Matthias Gaertner's decade-long tenure as CEO, during which he significantly influenced Medios AG's growth and success. Gaertner will remain in office until December 31, 2025, ensuring a smooth handover process. This carefully managed transition period reflects the company's commitment to operational stability while implementing strategic leadership changes. The appointment of an executive with Meier's international CDMO experience suggests Medios AG may be positioning itself for expanded manufacturing capabilities or enhanced partnership opportunities within the specialty pharmaceutical ecosystem.

For shareholders and market participants, this leadership change comes as Medios AG shares continue trading on the regulated market of the Frankfurt Stock Exchange under Prime Standard listing and inclusion in the SDAX selection index. The company's upcoming participation in investor conferences, including the mwb inspired Conference in Hamburg on November 12 and the Berenberg European Conference at Fairmont Windsor Park in December, will provide additional opportunities for the new leadership to articulate its strategic vision. Additional corporate information is available at https://www.medios.group.